Product Overview
Compound
excipients: sodium chloride - 0.045 g, water for injection - up to 5 ml.
pharmachologic effect
PHARMACOTHERAPEUTIC GROUP:
Antiviral and immunomodulatory agent.
ATX CODE: J05AX.
PHARMACOLOGICAL PROPERTIES
Pharmacodynamics
Panavir® - purified extract of shoots of the Solanum tuberosum plant; the main active ingredient is a hexose glycoside consisting of glucose, rhamnose, arabinose, mannose, xylose, galactose, and uronic acids.
The drug Panavir® is an antiviral and immunomodulatory agent. Increases the body's nonspecific resistance to various infections and promotes the induction of alpha and gamma interferons by blood leukocytes.
In therapeutic doses, the drug is well tolerated.
Tests have shown the absence of mutagenic, teratogenic, carcinogenic, allergenic and embryotoxic effects. In preclinical studies on laboratory animals, no negative effects on reproductive function and fetal development were established.
It has anti-inflammatory properties in experimental models of exudative edema, chronic proliferative inflammation and in the pseudoallergic inflammatory reaction test to concanavalin A.
An analgesic effect has been shown in models of neurogenic pain and pain caused by inflammation and thermal irritation.
Has an antipyretic effect.
In a model of parkinsonian syndrome caused by systemic administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, neuroprotective properties were shown.
Has the ability to improve the functions of the retina and optic nerve.
It has wound-healing properties in a gastric ulcer model.
Pharmacokinetics
When administered intravenously, polysaccharides are detected in the blood within 5 minutes after administration and are captured by the cells of the reticuloendothelial system of the liver and spleen. Elimination begins quickly; after 20-30 minutes, polysaccharides are found in the urine and exhaled air.
Indications
• Secondary immunodeficiency states due to infectious diseases.
• Cytomegalovirus infection, including in patients with recurrent miscarriage.
• Used in women with chronic viral infection and interferon deficiency in preparation for pregnancy.
• Chronic cytomegalovirus infection in the acute stage in pregnant women in the 2nd and 3rd trimester as part of complex therapy.
• Human papillomavirus infection (anogenital warts) as part of complex therapy.
• Peptic ulcer of the stomach and duodenum in patients with long-term scarring ulcers and symptomatic ulcers of the gastroduodenal zone as part of complex therapy.
• Tick-borne encephalitis to reduce the viral load and relieve neurological symptoms (anisoreflexia, decreased reflexes, pain at the exit points of cranial nerves, nystagmus) as part of complex therapy.
• Rheumatoid arthritis combined with herpesvirus infection in immunocompromised patients (to enhance the analgesic and anti-inflammatory effect of the main therapy), as part of complex therapy.
• ARVI and influenza as part of complex therapy.
• Panavir® is used in complex therapy of chronic bacterial prostatitis.
Use during pregnancy and breastfeeding
Contraindications
• Lactation period.
• Children under 12 years of age.
Side effects
The drug is well tolerated; possible complications may be associated with individual intolerance and hypersensitivity to the components of the drug.
Interaction
Not found.
How to take, course of administration and dosage
• The therapeutic dose of the drug is 200 mcg of active substance (contents of one ampoule or bottle).
• For the treatment of herpes virus infections and tick-borne encephalitis, apply twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month.
• For the treatment of cytomegalovirus and human papillomavirus infections, it is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours. • For the
treatment of chronic cytomegalovirus infection in the acute stage in pregnant women in the second and third trimester, it is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.
• For the treatment of gastric and duodenal ulcers in the acute phase and symptomatic ulcers of the gastroduodenal zone, 5 intravenous injections are used every other day for 10 days.
• For the treatment of rheumatoid arthritis combined with herpesvirus infection in immunocompromised patients, 5 intravenous injections are used with an interval of 24-48 hours, if necessary, repeat the course after 2 months.
• For the treatment of ARVI and influenza, 2 intravenous injections are used with an interval of 18-24 hours.
• For the treatment of patients with chronic bacterial prostatitis, 5 intravenous injections are used with an interval of 48 hours.
APPLICATION IN PEDIATRICS
Panavir® is prescribed to children from 12 years of age at a dose of 100 mcg intravenously 1 once a day.
For the treatment of herpes virus infections and tick-borne encephalitis, it is used twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month.
For the treatment of cytomegalovirus and human papillomavirus infections, it is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.
Overdose
Description
Special instructions
If the solution becomes cloudy, the drug is considered unsuitable for use.
INFLUENCE ON THE ABILITY TO DRIVE VEHICLES AND MECHANISMS
There is no data on the possibility of a negative effect of the drug on the ability to drive vehicles and carry out potentially hazardous activities that require special attention and speed of psychomotor reactions.
Release form
5 ml of solution in ampoules or neutral glass bottles with a capacity of 5 ml, sealed with rubber stoppers with rolled aluminum caps.
2 or 5 ampoules in a blister pack, 1 blister pack of 2 or 5 ampoules, 2 blister packs of 5 ampoules each, along with instructions for use and an ampoule knife or scarifier in a cardboard pack.
When packaging in ampoules with a colored dot and a cut or a colored break ring on the ampoule, a scarifier or ampoule knife is not inserted.
2 or 5 bottles in a blister pack, 1 blister pack of 2 or 5 bottles, 2 blister packs of 5 bottles each, along with instructions for use in a cardboard pack.
Storage conditions
Best before date
Do not use after the expiration date stated on the package.
